<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335049">
  <stage>Registered</stage>
  <submitdate>27/01/2010</submitdate>
  <approvaldate>4/02/2010</approvaldate>
  <actrnumber>ACTRN12610000119099</actrnumber>
  <trial_identification>
    <studytitle>Study for the assessment of clinical non-inferiority and tolerability of Estrogenon (Sanval Comercio e Industria Ltda) in comparasion to Premarin (Wyeth Industria Farmaceutica Ltda) in women post menopause.</studytitle>
    <scientifictitle>Study for the assessment of clinical non-inferiority and tolerability of Estrogenon drug  conjugated estrogens, coated tablets coated tablet manufactured by Sanval  Comercio e Industria Ltda. in comparison to (PREMARIN) coated tablets  manufactured by Wyeth Industria Farmaceutica Ltda. in women post menopause</scientifictitle>
    <utrn>U1111-1113-4072</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Study with the purpose of check clinical non- inferiority and tolerance of conjugated estrogen coated tablet manufactured by different manufactures</healthcondition>
    <healthcondition>Women in post menopause with indications for estrogens  replacement therapy.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Estrogen drug - conjugated estrogens, coated tablets 0,625mg/coated tablet manufactured by Sanval Comercio e Industria Ltda,taken orally once a day for a total of 90 days, in comparasion to Premarin 0,625 mg/coated tablet manufactured by Wyeth Industria Farmaceutica Ltda, taken orally once a day also for a total of 90 days.</interventions>
    <comparator>Comparison of action of two differents coated tablet of conjugated estrogens 0625mg/coated tablet, taken orally once a day, during 90 days on a clinical setting.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endometium thickness; alterations in clinical examination (gynecological)</outcome>
      <timepoint>at 90 days from baseline.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women in menopause with indications for estrogen replacement therapy.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Patients with contraindications for estrogen use.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanval Comercio e Industria Ltda</primarysponsorname>
    <primarysponsoraddress>Rua Lagrange 401 - Socorro - Sao Paulo - Brazil - 04761-050</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanval Comercio e Industria Ltda</fundingname>
      <fundingaddress>Rua Lagrange 401 - Socorro - Sao Paulo - Brazil - 04761-050</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients at post-menopause phase, after signing Free and Informed Consent Term, shall pass through medical consultation and laboratorial exams (clinical analysis) including plasmatic dosing of Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Glutamate Oxaloacetate Transaminase (GOT) and glutamic-pyruvic transaminase (GPT), calcium and Total Estrogen (Estradiol) and Free Estrogen (Free Estriol), Glucose and total Cholesterol. A mammography will be performed in order to exclude patients with counter indication for the drug use. Patients shall be sent to undergo transvaginal ultrasound exam in order to assess their endometrium thickness. During medical consultation, vaginal walls as well as the cervix will be scraped for functional cytological and oncologic exam, using Papanicolaou test method. The procedures, in total or in part, shall be repeated at the following visits, within three months follow-up time period.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisa do Hospital Belo Horizonte</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/03/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Marco Tulio Bacarrini Pires PhD</name>
      <address>Av. do contorno 2646 - 6ยบ andar - Belo Horizonte - Minas Gerais - 30110-014</address>
      <phone>+553132483458</phone>
      <fax>+553132483458</fax>
      <email>mtbpires@cebio.med.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jose Aurelio Quintao Sarmento</name>
      <address>Av. Nicolau Alayon 441, Interlagos, Sao Paulo - 04802-000</address>
      <phone>+551156604001</phone>
      <fax>+551156668664</fax>
      <email>aurelio.sarmento@sanval.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>